Jajini Varghese
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jajini Varghese has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Kathrine Sofia Rallis
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
2 shared publications - Anni Lepland
Genetics and Personalized Medicine Clinic, Tartu University Hospital, 50406 Tartu, Estonia
1 shared publication - Ave-Triin Tihamäe
Clinic of Surgery, Tartu University Hospital, 50406 Tartu, Estonia
1 shared publication - B.R.H. Turner
Department of Plastic Surgery, Royal Free Hospital, London, United Kingdom; Charles Wolfson Center for Reconstructive Surgery, Royal Free Hospital, London, United Kingdom
1 shared publication - Benjamin J. Langridge
Charles Wolfson Centre for Reconstructive Surgery, Royal Free Hospital, London NW3 2QG, UK
1 shared publication - Berta Obispo
Medical Oncology Service, Infanta Leonor University Hospital, Vallecas, 28031 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 1 April 2026
- Published by SAGE Publications in JRSM Open
- Vol. 17 (4)
Effect of COVID-19 NHS breast screening pause on breast cancer presentation and management: an insight into overdiagnosis
Objective: To ascertain the impact of a 3-month pause in the NHS Breast Screening Programme (NHSBSP) during COVID-19 on numbers, characteristics and outcomes of breast cancer patients Design: We compared numbers, referral sources (NHSBSP/GP), tumour characteristics, treatments, and survival before and during COVID-19 using chi-square tests and Kaplan-Meier estimates. Patients were grouped into: (a) all cases from 2019 to 2021 ( n = 3353) and (b) six selected months in 2019 and 2020 ( n = 325). Setting: The study was conducted with the breast units of two large London NHS hospitals as a local audit to understand the impact of COVID-19 on breast cancer management. Participants: Patients diagnosed with breast cancer from 2019 to 2021 were analysed. Main outcome measures: Temporal variation in the number of breast cancer cases by referral source and the impact of the pause in screening mammography due to the COVID-19 pandemic on changes in tumour characteristics, treatments and survival. Results: Overall, there were 31% fewer patients in 2020 vs. 2019 (886 vs. 1281, p = .002), due to fewer screen-detected (851 vs. 398) rather than symptomatic cases (432 vs. 459), p < .00001), with no corresponding increase in 2021 ( n = 1186) In the detailed analysis, there were significantly fewer grade 1 cancers (11/120 vs. 37/204, p = .028) in 2020 vs. 2019, but there was no stage shift from smaller or less advanced (node-negative) tumours to larger or more advanced tumours, and no difference in extent of surgery, i.e., ratios of breast conservation to mastectomy, or sentinel node biopsy to axillary clearance. There was no difference in time from referral to diagnosis between the two time periods. The median follow-up was 3.8 years; K-M survival curves overlapped, with no difference in 3-year survival (90.5% vs. 91.7%, HR=1.09, p = .83). Conclusions: During the COVID-19-induced NHSBSP pause, good-prognosis (grade 1) cancers reduced without an increase in larger, or node-positive cancers, or more extensive surgery, and 3-year survival remained unchanged, suggesting that pausing NHSBSP may have avoided overdiagnosis without causing harm.
- 1 April 2026
- Published by SAGE Publications in JRSM Open
- Vol. 17 (4)
Open AccessEffect of COVID-19 NHS breast screening pause on breast cancer presentation and management: an insight into overdiagnosis
Objective: To ascertain the impact of a 3-month pause in the NHS Breast Screening Programme (NHSBSP) during COVID-19 on numbers, characteristics and outcomes of breast cancer patients Design: We compared numbers, referral sources (NHSBSP/GP), tumour characteristics, treatments, and survival before and during COVID-19 using chi-square tests and Kaplan-Meier estimates. Patients were grouped into: (a) all cases from 2019 to 2021 ( n = 3353) and (b) six selected months in 2019 and 2020 ( n = 325). Setting: The study was conducted with the breast units of two large London NHS hospitals as a local audit to understand the impact of COVID-19 on breast cancer management. Participants: Patients diagnosed with breast cancer from 2019 to 2021 were analysed. Main outcome measures: Temporal variation in the number of breast cancer cases by referral source and the impact of the pause in screening mammography due to the COVID-19 pandemic on changes in tumour characteristics, treatments and survival. Results: Overall, there were 31% fewer patients in 2020 vs. 2019 (886 vs. 1281, p = .002), due to fewer screen-detected (851 vs. 398) rather than symptomatic cases (432 vs. 459), p < .00001), with no corresponding increase in 2021 ( n = 1186) In the detailed analysis, there were significantly fewer grade 1 cancers (11/120 vs. 37/204, p = .028) in 2020 vs. 2019, but there was no stage shift from smaller or less advanced (node-negative) tumours to larger or more advanced tumours, and no difference in extent of surgery, i.e., ratios of breast conservation to mastectomy, or sentinel node biopsy to axillary clearance. There was no difference in time from referral to diagnosis between the two time periods. The median follow-up was 3.8 years; K-M survival curves overlapped, with no difference in 3-year survival (90.5% vs. 91.7%, HR=1.09, p = .83). Conclusions: During the COVID-19-induced NHSBSP pause, good-prognosis (grade 1) cancers reduced without an increase in larger, or node-positive cancers, or more extensive surgery, and 3-year survival remained unchanged, suggesting that pausing NHSBSP may have avoided overdiagnosis without causing harm.
- Open Access
Long-Term Adverse Events Following Early Breast Cancer Treatment with a Focus on the BRCA-Mutated Population
Breast cancer (BC) is the most prevalent malignancy in women worldwide. Despite most cases being diagnosed in the early stages, patients typically require a multimodal treatment approach. This typically involves a combination of surgery, radiotherapy, systemic treatments (including chemotherapy or immunotherapy), targeted therapy, and endocrine therapy, depending on the disease subtype and the risk of recurrence. Moreover, patients with BC and germline mutations in the breast cancer genes 1 or 2 (BRCA1/BRCA2), (gBRCAm), who are typically young women, often require more aggressive therapeutic interventions. These mutations present unique characteristics that necessitate a distinct treatment approach, potentially influencing the side effect profiles of patients with BC. Regardless of the clear benefit observed with these treatments in terms of reduced recurrence and mortality rates, long-term, treatment-related adverse events occur that negatively affect the health-related quality of life (HRQoL) of BC survivors. Thus, long-term adverse events need to be factored into the treatment decision algorithm of patients with early BC (eBC). Physical, functional, emotional, and psychosocial adverse events can occur and represent a significant concern and a challenge for clinicians, patients, and their families. This review article provides an overview of the various long-term adverse events that patients with eBC may experience, including their associated risk factors, as well as management and prevention strategies. We also explore the evidence of the long-term impact of treatment on the HRQoL of patients with gBRCAm. By providing a comprehensive overview of current evidence and recommendations regarding patients’ HRQoL, we aim to equip clinicians with scientific and clinical knowledge and provide guidance to optimize care and improve long-term outcomes.
Open AccessLong-Term Adverse Events Following Early Breast Cancer Treatment with a Focus on the BRCA-Mutated Population
Breast cancer (BC) is the most prevalent malignancy in women worldwide. Despite most cases being diagnosed in the early stages, patients typically require a multimodal treatment approach. This typically involves a combination of surgery, radiotherapy, systemic treatments (including chemotherapy or immunotherapy), targeted therapy, and endocrine therapy, depending on the disease subtype and the risk of recurrence. Moreover, patients with BC and germline mutations in the breast cancer genes 1 or 2 (BRCA1/BRCA2), (gBRCAm), who are typically young women, often require more aggressive therapeutic interventions. These mutations present unique characteristics that necessitate a distinct treatment approach, potentially influencing the side effect profiles of patients with BC. Regardless of the clear benefit observed with these treatments in terms of reduced recurrence and mortality rates, long-term, treatment-related adverse events occur that negatively affect the health-related quality of life (HRQoL) of BC survivors. Thus, long-term adverse events need to be factored into the treatment decision algorithm of patients with early BC (eBC). Physical, functional, emotional, and psychosocial adverse events can occur and represent a significant concern and a challenge for clinicians, patients, and their families. This review article provides an overview of the various long-term adverse events that patients with eBC may experience, including their associated risk factors, as well as management and prevention strategies. We also explore the evidence of the long-term impact of treatment on the HRQoL of patients with gBRCAm. By providing a comprehensive overview of current evidence and recommendations regarding patients’ HRQoL, we aim to equip clinicians with scientific and clinical knowledge and provide guidance to optimize care and improve long-term outcomes.
- Open Access
Guidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are increasingly applied in healthcare. One of the most studied and developed areas is predictive medicine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. This current guidance endeavours to articulate the scientific evidence underpinning the clinical utility of PRSs in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: This guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opinion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRSs can be divided into the following scenarios: (1) Management of cancer-free women with a family history of cancer; (2) individual personalised breast cancer prevention and screening in healthcare services; and (3) breast cancer screening programs for more personalised screening. Conclusions: The integration of PRSs into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, supporting a personalised, risk-based approach to breast cancer prevention and screening.
Open AccessGuidance for the Clinical Use of the Breast Cancer Polygenic Risk Scores
Background/Objectives: Polygenic risk scores (PRSs) have been extensively studied and are increasingly applied in healthcare. One of the most studied and developed areas is predictive medicine for breast cancer, but there is no wider consensus on the indications for the clinical use of PRSs for breast cancer. This current guidance endeavours to articulate the scientific evidence underpinning the clinical utility of PRSs in stratifying breast cancer risk, with a particular emphasis on clinical application. Methods: This guidance has been prepared by a group of experts who have been active in breast cancer PRS research and development, combining a review of the evidence base with expert opinion for indications for clinical use. Results: Based on data from various studies and existing breast cancer prevention and screening services, the indications for clinical use of breast cancer PRSs can be divided into the following scenarios: (1) Management of cancer-free women with a family history of cancer; (2) individual personalised breast cancer prevention and screening in healthcare services; and (3) breast cancer screening programs for more personalised screening. Conclusions: The integration of PRSs into clinical practice enables healthcare providers to deliver more accurate risk assessments, personalised prevention strategies, and optimised screening programmes, thereby improving patient outcomes and enhancing the effectiveness of breast cancer care. PRS testing represents a novel component in clinical breast cancer risk assessment, supporting a personalised, risk-based approach to breast cancer prevention and screening.
- Open Access
Omitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
Recent advances in systemic treatment for breast cancer have been underpinned by recognising and exploiting subtype-specific vulnerabilities to achieve higher rates of pathologic complete response (pCR) after neo-adjuvant systemic therapy (NAST). This down-staging of disease has permitted safe surgical de-escalation in patients who respond well. Triple-negative (TNBC) or HER2-positive breast cancer is most likely to achieve complete radiological response (rCR) and pCR after NAST. Hence, for selected patients, particularly those who are clinically node-negative (cN0) at diagnosis, the probability of disease in the sentinel node after NAST could be low enough to justify omitting axillary surgery. The aim of this pooled analysis was to determine the rate of sentinel node positivity (ypN+) in patients with TNBC or HER2-positive breast cancer who were initially cN0, achieving rCR and/or pCR in the breast after NAST. MedLine was searched using appropriate search terms. Five studies (N = 3834) were included in the pooled analysis, yielding a pooled ypN+ rate of 2.16% (95% CI: 1.70–2.63). This is significantly lower than the acceptable false negative rate of sentinel lymph node biopsy (SLNB) and supports consideration of omission of SLNB in this subset of patients.
Open AccessOmitting Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy for Clinically Node Negative HER2 Positive and Triple Negative Breast Cancer: A Pooled Analysis
Recent advances in systemic treatment for breast cancer have been underpinned by recognising and exploiting subtype-specific vulnerabilities to achieve higher rates of pathologic complete response (pCR) after neo-adjuvant systemic therapy (NAST). This down-staging of disease has permitted safe surgical de-escalation in patients who respond well. Triple-negative (TNBC) or HER2-positive breast cancer is most likely to achieve complete radiological response (rCR) and pCR after NAST. Hence, for selected patients, particularly those who are clinically node-negative (cN0) at diagnosis, the probability of disease in the sentinel node after NAST could be low enough to justify omitting axillary surgery. The aim of this pooled analysis was to determine the rate of sentinel node positivity (ypN+) in patients with TNBC or HER2-positive breast cancer who were initially cN0, achieving rCR and/or pCR in the breast after NAST. MedLine was searched using appropriate search terms. Five studies (N = 3834) were included in the pooled analysis, yielding a pooled ypN+ rate of 2.16% (95% CI: 1.70–2.63). This is significantly lower than the acceptable false negative rate of sentinel lymph node biopsy (SLNB) and supports consideration of omission of SLNB in this subset of patients.
- 13 February 2023
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 81, 9-25
Achieving optimal clinical outcomes in autologous fat grafting: A systematic review of processing techniques
- 13 February 2023
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 81, 9-25
Achieving optimal clinical outcomes in autologous fat grafting: A systematic review of processing techniques
- Open Access
- 16 May 2022
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (11) , 699-709
Complex Cross-Talk between EZH2 and Mirnas Confers Hallmark Characteristics and Shapes the Tumor Microenvironment
Cancer epigenetic mechanisms support the acquisition of hallmark characteristics during oncogenesis. EZH2 – an important histone methyltransferase that writes histone H3 lysine 27 trimethylation ma... Plain language summary Cancer epigenetics involves cellular processes that ensure that gene expression changes that enable cancer cells to outcompete their neighboring normal tissues are passed on ...
- 16 May 2022
- Published by Taylor & Francis in Epigenomics
- Vol. 14 (11) , 699-709
Open AccessComplex Cross-Talk between EZH2 and Mirnas Confers Hallmark Characteristics and Shapes the Tumor Microenvironment
Cancer epigenetic mechanisms support the acquisition of hallmark characteristics during oncogenesis. EZH2 – an important histone methyltransferase that writes histone H3 lysine 27 trimethylation ma... Plain language summary Cancer epigenetics involves cellular processes that ensure that gene expression changes that enable cancer cells to outcompete their neighboring normal tissues are passed on ...
- Open Access
- 27 November 2020
- Published by Springer Nature in Cureus
- Vol. 12 (11)
Advances in Epigenetic Cancer Therapeutics
Cancer has traditionally been hailed a genetic disease, dictated by successive genetic aberrations which alter gene expression. Yet, recent advances in molecular sequencing technologies, enabling the characterisation of cancer patient phenotypes on a large scale, have highlighted epigenetic changes as a hallmark of cancer. Epigenetic modifications, including DNA methylation and demethylation and histone modifications, have been found to play a key role in the pathogenesis of a wide variety of cancers through the regulation of chromatin state, gene expression and other nuclear events. Targeting epigenetic aberrations offers remarkable promise as a potential anti-cancer therapy given the reversible nature of epigenetic changes. Hence, epigenetic therapy has emerged as a rapidly advancing field of cancer research. A plethora of epigenetic therapies which inhibit enzymes of post-translational histone modifications, so-called ‘writers’, ‘erasers’ and ‘readers’, have been developed, with several epigenetic inhibitor agents approved for use in routine clinical practice. Epigenetic therapeutics inhibit the methylation or demethylation and acetylation or deacetylation of DNA and histone proteins. Their targets include writers (DNA methyltransferases [DNMT], histone acetyltransferases [HAT] and histone deacetylases [HDAC]) and erasers (histone demethylases [HDM] and histone methylases [HMT]). With new epigenetic mechanisms increasingly being elucidated, a vast array of targets and therapeutics have been brought to the fore. This review discusses recent advances in cancer epigenetics with a focus on molecular targets and mechanisms of action of epigenetic cancer therapeutics.
- 27 November 2020
- Published by Springer Nature in Cureus
- Vol. 12 (11)
Open AccessAdvances in Epigenetic Cancer Therapeutics
Cancer has traditionally been hailed a genetic disease, dictated by successive genetic aberrations which alter gene expression. Yet, recent advances in molecular sequencing technologies, enabling the characterisation of cancer patient phenotypes on a large scale, have highlighted epigenetic changes as a hallmark of cancer. Epigenetic modifications, including DNA methylation and demethylation and histone modifications, have been found to play a key role in the pathogenesis of a wide variety of cancers through the regulation of chromatin state, gene expression and other nuclear events. Targeting epigenetic aberrations offers remarkable promise as a potential anti-cancer therapy given the reversible nature of epigenetic changes. Hence, epigenetic therapy has emerged as a rapidly advancing field of cancer research. A plethora of epigenetic therapies which inhibit enzymes of post-translational histone modifications, so-called ‘writers’, ‘erasers’ and ‘readers’, have been developed, with several epigenetic inhibitor agents approved for use in routine clinical practice. Epigenetic therapeutics inhibit the methylation or demethylation and acetylation or deacetylation of DNA and histone proteins. Their targets include writers (DNA methyltransferases [DNMT], histone acetyltransferases [HAT] and histone deacetylases [HDAC]) and erasers (histone demethylases [HDM] and histone methylases [HMT]). With new epigenetic mechanisms increasingly being elucidated, a vast array of targets and therapeutics have been brought to the fore. This review discusses recent advances in cancer epigenetics with a focus on molecular targets and mechanisms of action of epigenetic cancer therapeutics.